AstraZeneca Makes European IO Debut With Imfinzi Lung Cancer Approval

 
• By Eleanor Malone

Imfinzi will be the fourth PD-1/L1 inhibitor approved for lung cancer in Europe, but AstraZeneca could carve out a niche by being indicated for sequential use following chemoradiation.

Business niche market and specializing in a smaller opportunity as an individual dart going a different way as a metaphor for strategic planning as a 3D illustration.
Late to market but targeting a new niche: Imfinzi • Source: Shutterstock

More from New Products

More from Scrip